Antimicrobial Bioadhesive Polymer Complexes for the Oral Cavity

Total Page:16

File Type:pdf, Size:1020Kb

Antimicrobial Bioadhesive Polymer Complexes for the Oral Cavity ANTIMICROBIAL BIOADHESIVE POLYMER COMPLEXES FOR THE ORAL CAVITY GEMMA KEEGAN A thesis submitted in partial fulfilment of the requirements of the University of Brighton for the degree of Doctor of Philosophy March 2007 The University of Brighton in collaboration with GlaxoSmithKline. -2- ABSTRACT Due to the problems associated with local antimicrobial delivery to the oral cavity, such as poor retention times, the use ofbioadhesive polymers within oral healthcare products may significantly improve therapeutic efficacy. In the current study, bioadhesive antimicrobial-polymer complexes were investigated as a formulation strategy to improve the substantivity of antimicrobial compounds within the oral cavity. Interactions between Carbopol'P' polymers and antimicrobial metals were investigated using a dialysis technique. Carbopol 971P-zinc complexes exhibited ideal properties, with zinc retained by the polymer in deionised water and displaced in the presence of sodium chloride and calcium chloride at a rate determined by the pH of the solution. Carbopol 971P-silver and Carbopol 971P-copper complexes were both retained by the polymer in deionised water but did not demonstrate ideal displacement in the presence of competing ions. Both Carbopol 971P-zinc and Carbopol 971P-silver complexes exhibited bioadhesive properties comparable to the polymer alone when assessed using an in vitro staining technique and texture probe analysis, however Carbopol 971P- copper adhesion was significantly reduced. Interactions between chitosan and fluoride did not prevent fluoride release in deionised water when using the dialysis technique, therefore microparticles were formulated using a water-in-oil solvent evaporation technique and by spray-drying. Spray-dried fluoride microparticles exhibited a smaller size distribution, sustained fluoride release, improved fluoride loading and bioadhesion to oesophageal epithelium when compared to particles prepared from a water-in-oil solvent evaporation technique. Scanning electron microscopy revealed the presence of crystals on the surface of particles prepared by water-in-oil solvent evaporation, which were absent in particles prepared by spray- drying. Higher starting concentrations of chitosan were found to improve the fluoride loading of spray-dried microparticles; however the addition of glutaraldehyde had no significant effect on the parameters measured. Antimicrobial activity was initially assessed usmg a broth microdilution technique against a range of planktonic oral bacteria. Optimised chitosan-fluoride microparticles -3- demonstrated some activity at the highest concentration tested but was not effective against all species tested. Antimicrobial assessment of Carbopol 971P-zinc complexes suggested a lack of zinc bioavailability, possibly due to the lack of displacement Subsequent assessment of metal salts alone established the antimicrobial activity of zinc and silver, with copper demonstrating the lowest efficacy. The use of a bioavailability model developed at GlaxoSmithKline found no improvement in zinc or silver efficacy when formulated with Carbopol 971P in preventing the formation of a biofilm on hydroxyapatite. Despite the lack of significant antimicrobial effects, the potential for bioadhesive polymers in the improvement of antimicrobial retention within the oral cavity has been demonstrated through the characteristics of the complexes formed. -4- TABLE OF CONTENTS ABSTRACT 2 TABLE OF CONTENTS 4 ACKNOWLEGDEMENTS 9 AUTHOR'S DECLARATION 10 CHAPTER 1: 11 GENERAL INTRODUCTION 11 1.1 THE ORAL CAVITY 12 1.1.10VERVIEW 12 1.1.2 THE TEETH 12 1.1.3 THE ORALMUCOSA 13 1.1.4 SALIVA 15 1.1.5 MICROBIALECOLOGYOFTHEORALCAVITY 17 1.1.5.1 Dental plaque 20 1.2 DENTAL DISEASES 21 1.2.1 DENTALCARIES 21 1.2.2 PERIODONTALDISEASE 22 1.2.2.1 Gingivitis 23 1.2.2.2 Periodontitis 24 1.3 ORAL HEALTHCARE 2S 1.3.1 ORAL HEALTHCAREPRODUCTS 25 1.3.2 ANTIMICROBIALSIN ORALHEALTHCARE 27 1.3.3 CONSIDERATIONSANDLIMITAnONS IN ANTIMICROBIALORALHEALTHCARE. 29 1.3.3.1 Human oral retention and clearance 29 1.3.3.2 Emerging microbial resistance 30 1.3.3.3 In vitro vs. in vivo 31 1.3.3.4 Formulation 32 1.4 BIOADHESION 33 1.4.1 THE THEORIESOFADHESION 33 1.4.1.1 The electronic theory 34 1.4.1.2 The adsorption theory 34 1.4.1.3 The diffusion theory 34 1.4.1.4 The wetting theory 35 1.4.1.5 The fracture theory 35 1.4.2 MUCOADHESION 36 1.4.2.1 The contact stage 36 1.4.2.2 The consolidation stage 37 1.4.3 FACTORSIMPORTANTTOMUCOADHESION 39 1.4.4 METHODSTODETERMINEMUCOADHES[ON 40 1.4.4.1In vitro test methods 40 1.4.4.2In vivo test methods 42 1.4.4 MUCOADHESIVEPOLYMERS 43 - 5 - 1.4.4.1 Poly(acrylic acid)-based polymers 44 1.4.4.1a Carbopol 44 1.4.4.1 b Polycarbophil 45 1.4.4.2 Chitosan-based polymers 45 1.4.4.3 Other mucoadhesive polymers 46 1.4.4.3a Cellulose-based polymers 46 1.4.4.3b Natural polysaccharides 46 1.4.4.3c Other synthetic polymers 48 1.4.5 MUCOADHESIVEDRUGANDANTIMICROBIALDELIVERYIN THE ORALCAVITY 48 1.4.5.1 Solid dosage forms 48 1.4.5.2 Semi-solid dosage forms 51 1.4.5.3 Liquid dosage forms 53 1.4.5.4 Particulate systems 54 1.4.6 A NEW DEVELOPMENTINANTIMICROBIALTHERAPYWITHINTHE ORALCAVITY 55 1.5 AIMS AND OBJECTIVES 57 CHAPTER2 58 IN VITRO ASSESSMENT OF BIOADHESIVE POLYMERS 58 2.1. INTRODUCTION 59 2.Ll BACKGROUND 59 2.1.2 DETECTINGPOLYMERONCELL SURFACES:HISTOLOGICALSTAININGAND DYES 60 2.1.3 MEASURINGADHESIVEBONDSTRENGTH:TEXTUREPROBEANALYSIS 61 2.2 MATERIALS ANDMETHODS 65 2.2.1 MATERIALS 65 2.2.2 METHODS 65 2.2.2.1 In vitro direct staining technique 65 2.2.2.1 a Preparation of aqueous polymer dispersions 65 2.2.2.1 b In vitro mucoadhesion of polymer dispersions to human buccal cells in sucrose 66 2.2.2.1 c In vitro mucoadhesion of polymer dispersions to human buccal cells in artificial saliva 66 2.2.2.ld Cell staining and analysis 67 2.2.2.2 Texture probe analysis 68 2.2.2.2a Preparation of polymer samples 68 2.2.2.2b Preparation of porcine oesophageal tissue 68 2.2.2.2c Texture probe analysis 68 2.2.3 STATISTICALANALYSIS 69 2.3 RESULTS AND DISCUSSION 70 2.3.1 IN VITRO STAlNlNGTECHNIQUE 70 2.3.1.1 Microscopy of treated cells 72 2.3.1.2 Stain intensity 75 2.3.2 TEXTURE PROBEANALYSIS 76 2.3.2.1 Poly(acrylic acid) based polymers 78 2.3.2.2 Chitosan polymers 81 2.4 CONCLUSIONS 87 CHAPTER3 88 DEVELOPMENT OF A POLY(ACRYLIC ACID)-METAL ION ORAL DELIVERY SYSTEM 88 -6- 3.1 INTRODUCTION 89 3.1.1 BACKGROUND 89 3.1.2 DIALYSIS: A METHODOF EVALUATINGTHERATEOF ACTIVEAGENTRELEASE. 90 3.1.3 METAL IONDETECTIONINSOLUTION- ATOMIC ABSORPTIONSPECTROSCOPY 92 3.2 MATERIALS ANDMETHODS 94 3.2.1 MATERIALS 94 3.2.2 METHODS 94 3.2.2.1 Preparation and characterisation of metal ion-polymer complexes 94 3.2.2.1 a Preparation of aqueous polymer dispersions and metal ion solutions 94 3.2.2.1b Development of Carbo pol 971P-metal salt solution 95 3.2.2.1c Stability of metal-polymer complex 95 3.2.2.1d Displacement of metal from the polymer complex 96 3.2.2.1e Atomic absorption spectroscopy 97 3.2.2.2 In vitro assessment ofbioadhesion I: Direct staining technique 98 3.2.2.2a In vitro mucoadhesion of polymer dispersions to human buccal cells in sucrose 98 3.2.2.2b In vitro mucoadhesion of polymer dispersions to human buccal cells in artificial saliva 98 3.2.2.2c Cell staining and analysis 99 3.2.2.3 In vitro assessment ofbioadhesion II: Texture probe analysis 99 3.2.2.3a Preparation of texture probe analysis samples 99 3.2.2.3b Porcine oesophageal tissue 99 3.2.2.3c Texture probe analysis 99 3.2.3 STATISTICALANALYSIS 100 3.3 RESULTS AND DISCUSSION 101 3.3.1 DEVELOPMENTOF CARBOPOL971P-METAL SALTSOLUTIONS 101 3.3.2 STABILITYOF CARBOPOL971P-METAL SALTCOMPLEX 103 3.3.3 DISPLACEMENTFROMTHE METAL-POLYMERCOMPLEX 108 3.3.4 IN VITROASSESSMENTOFBIOADHESIONI: DIRECT STAININGTECHNIQUE. 114 3.3.4.1 Bioadhesion in sucrose 114 3.3.4.2 Bioadhesion in artificial saliva 117 3.3.5 IN VITROASSESSMENTOFBIOADHESIONII: TEXTUREPROBEANALYSIS 120 3.4 CONCLUSIONS 124 CHAPTER 4 125 DEVELOPMENT OF A CHITOSAN-FLUORIDE ORAL DELIVERY SYSTEM 125 4.1 INTRODUCTION 126 4.1.1 BACKGROUND 126 4.1.2 DETECTINGFREEFLUORIDEUSINGPOTENTIOMETRY-FLUORIDEIONSELECTIVE ELECTRODES 127 4.1.3 MANUFACTURINGMICROPARTICLESBYSPRAYDRYING 129 4.1.4 PARTICLE SIZINGUSINGLASERDIFFRACTION 131 4.1.5 INVESTIGATINGMICROPARTICLEMORPHOLOGY-SCANNINGELECTRONMICROSCOPY 132 4.2 MATERIALS ANDMETHODS 135 4.2.1 MATERIALS 135 4.2.2 METHODS 135 4.2.2.1 Preparation and characterisation of chitosan-fluoride complexes 135 4.2.2.1a Preparation of polymer dispersions and fluoride solutions 135 4.2.2.1 b Stability of chitosan-fluoride complexes 136 4.2.2.1c Displacement of fluoride from the chitosan complex 137 4.2.2.2 Analysis of fluoride samples using an ion selective electrode 137 4.2.2.2a Preparation of ionic strength (IS) adjustment buffers 137 -7- 4.2.2.2b Preparation of calibration standards 138 4.2.2.2c Calibration of the ion selective electrode 138 4.2.2.2d Analysis of fluoride samples 139 4.2.2.3 Preparation of chitosan-fluoride microparticles 140 4.2.2.3a Preparation of aqueous phase 140 4.2.2.3b Preparation of micro particles using spray drying 140 4.2.2.3c Preparation of micro particles using water in oil (W/O) emulsion solvent evaporation technique 141 4.2.2.4 Characterisation of chitosan-fluoride microparticles 142 4.2.2.4a Particle size 142 4.2.2.4b Fluoride loading 142 4.2.2.4c In vitro fluoride release 143 4.2.2.4d Texture probe analysis 144 4.2.2.4e Scanning electron microscopy 144 4.2.3 STATISTICALANALYSIS 144 4.3 RESULTS AND DISCUSSION 146 4.3.1 DEVELOPMENTANDSTABILITYOFAQUEOUSCHITOSAN-FLUORIDECOMPLEXES 146 4.3.2 DISPLACEMENTOFSODIUMMONOFLUOROPHOSPHATEFROMCHITOSANINISOTONIC
Recommended publications
  • WHO Drug Information Vol. 12, No. 3, 1998
    WHO DRUG INFORMATION VOLUME 12 NUMBER 3 • 1998 RECOMMENDED INN LIST 40 INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA Volume 12, Number 3, 1998 World Health Organization, Geneva WHO Drug Information Contents Seratrodast and hepatic dysfunction 146 Meloxicam safety similar to other NSAIDs 147 Proxibarbal withdrawn from the market 147 General Policy Issues Cholestin an unapproved drug 147 Vigabatrin and visual defects 147 Starting materials for pharmaceutical products: safety concerns 129 Glycerol contaminated with diethylene glycol 129 ATC/DDD Classification (final) 148 Pharmaceutical excipients: certificates of analysis and vendor qualification 130 ATC/DDD Classification Quality assurance and supply of starting (temporary) 150 materials 132 Implementation of vendor certification 134 Control and safe trade in starting materials Essential Drugs for pharmaceuticals: recommendations 134 WHO Model Formulary: Immunosuppressives, antineoplastics and drugs used in palliative care Reports on Individual Drugs Immunosuppresive drugs 153 Tamoxifen in the prevention and treatment Azathioprine 153 of breast cancer 136 Ciclosporin 154 Selective serotonin re-uptake inhibitors and Cytotoxic drugs 154 withdrawal reactions 136 Asparaginase 157 Triclabendazole and fascioliasis 138 Bleomycin 157 Calcium folinate 157 Chlormethine 158 Current Topics Cisplatin 158 Reverse transcriptase activity in vaccines 140 Cyclophosphamide 158 Consumer protection and herbal remedies 141 Cytarabine 159 Indiscriminate antibiotic
    [Show full text]
  • United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar
    USOO896.9514B2 (12) United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar. 3, 2015 (54) AGONISTS OF GUANYLATECYCLASE 5,879.656 A 3, 1999 Waldman USEFUL FOR THE TREATMENT OF 36; A 6. 3: Watts tal HYPERCHOLESTEROLEMIA, 6,060,037- W - A 5, 2000 Waldmlegand et al. ATHEROSCLEROSIS, CORONARY HEART 6,235,782 B1 5/2001 NEW et al. DISEASE, GALLSTONE, OBESITY AND 7,041,786 B2 * 5/2006 Shailubhai et al. ........... 530.317 OTHER CARDOVASCULAR DISEASES 2002fOO78683 A1 6/2002 Katayama et al. 2002/O12817.6 A1 9/2002 Forssmann et al. (75) Inventor: Kunwar Shailubhai, Audubon, PA (US) 2003,2002/0143015 OO73628 A1 10/20024, 2003 ShaubhaiFryburg et al. 2005, OO16244 A1 1/2005 H 11 (73) Assignee: Synergy Pharmaceuticals, Inc., New 2005, OO32684 A1 2/2005 Syer York, NY (US) 2005/0267.197 A1 12/2005 Berlin 2006, OO86653 A1 4, 2006 St. Germain (*) Notice: Subject to any disclaimer, the term of this 299;s: A. 299; NS et al. patent is extended or adjusted under 35 2008/0137318 A1 6/2008 Rangarajetal.O U.S.C. 154(b) by 742 days. 2008. O151257 A1 6/2008 Yasuda et al. 2012/O196797 A1 8, 2012 Currie et al. (21) Appl. No.: 12/630,654 FOREIGN PATENT DOCUMENTS (22) Filed: Dec. 3, 2009 DE 19744O27 4f1999 (65) Prior Publication Data WO WO-8805306 T 1988 WO WO99,26567 A1 6, 1999 US 2010/O152118A1 Jun. 17, 2010 WO WO-0 125266 A1 4, 2001 WO WO-02062369 A2 8, 2002 Related U.S.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0158930 A1 Hirata Et Al
    US 2011 O15893 OA1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0158930 A1 Hirata et al. (43) Pub. Date: Jun. 30, 2011 (54) METHOD FOR TREATMENT OF RRTABLE Related U.S. Application Data BOWEL, SYNDROME (60) Provisional application No. 61/190.559, filed on Aug. 28, 2008. (75) Inventors: Takuya Hirata, Tokyo (JP); Toshiyuki Funatsu, Tokyo (JP); Publication Classification Yoshihiro Keto, Tokyo (JP); (51) Int. Cl. Shinobu Akuzawa, Tokyo (JP) A63L/78 (2006.01) C07D 403/06 (2006.01) (73) Assignee: ASTELLAS PHARMA INC., A6IPI/00 (2006.01) Tokyo (JP) A6IPL/T2 (2006.01) (52) U.S. Cl. ................................... 424/78.01: 548/302.7 (21) Appl. No.: 13/061,384 (57) ABSTRACT A method for treatment of a patient suffering from irritable (22) PCT Fled: Aug. 27, 2009 bowel syndrome with diarrhea or mixed irritable bowel syn drome, which comprises administering to the patient a thera (86) PCT NO.: PCT/UP2009/064904 peutically effective amount of ramosetron or a pharmaceuti cally acceptable salt thereof in combination with a S371 (c)(1), therapeutically effective amount of polycarbophil or a phar (2), (4) Date: Feb. 28, 2011 maceutically acceptable salt thereof. Patent Application Publication Jun. 30, 2011 Sheet 1 of 2 US 2011/O1589.30 A1 Fig.1 s 120 aw *e 100 aS$ 100 80 isd 80 v s 60 se sk sk 60 40 6 40 se g 20 20 - a k es O -- - - - , , , g- O W 0. 0.3 1 100 300 000 0.3 g/kg 300 mg/kg 0.3 g/kg + s S.
    [Show full text]
  • MEDEL: Medicare Part D Excluded Drugs
    MEDEL Medicare Part D Excluded Drugs Eligible for Coverage under MEDEL Only drugs provided by MEDEL participating manufacturers will be eligible for coverage. These drugs will maintain the current MEDEL Formulary with enforcement of its existing edits: PDL, Dosage Limitations, etc. Drug Categories / Drug Description Exclusion Cat Drug Categories / Drug Description Exclusion Cat ANALGESICS - MISC. Antidiarrheal Agents - Misc. Salicylates Bismuth Subsalicylate OTC Aspirin OTC Antacids - Aluminum Salts Analgesics Other Aluminum Hydroxide Gel OTC Acetaminophen OTC Antacids - Bicarbonate ANTIASTHMATIC - NASAL MISC. Sodium Bicarbonate (Antacid) OTC Nasal Agents - Misc. Antacids - Calcium Salts Saline OTC ANTICONVULSANTS Calcium Carbonate (Antacid) OTC Anticonvulsants - Benzodiazepines Antacids - Magnesium Salts Clonazepam Benzodiazepines Magnesium Oxide OTC Diazepam (Anticonvulsant) Benzodiazepines Antacid Combinations ANTIHISTAMINES - NON-SEDATING Aluminum & Magnesium Hydroxide OTC Antihistamines - Non-Sedating GI - ANTIPERISTALTIC AGENTS CLARITIN OTC Antiperistaltic Agents loratadine OTC ANXIOLYTICS - BENZODIAZEPINES Loperamide HCl OTC GI - DIGESTIVE ENZYMES Benzodiazepines Digestive Enzymes Alprazolam Benzodiazepines Chlordiazepoxide HCl Benzodiazepines Lactase OTC Clorazepate Dipotassium Benzodiazepines GI - H2-ANTAGONISTS Diazepam Benzodiazepines Lorazepam Benzodiazepines H-2 Antagonists Oxazepam Benzodiazepines Cimetidine OTC COUGH/COLD Famotidine OTC Ranitidine HCl OTC Systemic Decongestants GI - MISC. Pseudoephedrine HCl OTC Saline
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,986,901 B2 Meisel Et Al
    USOO698.6901B2 (12) United States Patent (10) Patent No.: US 6,986,901 B2 Meisel et al. (45) Date of Patent: Jan. 17, 2006 (54) GASTROINTESTINAL COMPOSITIONS 6,121,301 A 9/2000 Nagasawa et al. 6,127,418 A 10/2000 Bueno et al. (75) Inventors: Gerard M. Meisel, Budd Lake, NJ 6,156,771. A 12/2000 Rubin et al. S. Arthur A. Ciociola, Far Hills, NJ FOREIGN PATENT DOCUMENTS CA 967977 5/1975 (73) Assignee: Warner-Lambert Company LLC, CA 2136164 3/1995 Morris Plains, NJ (US) CN 1092314 3/1993 CN 1118267 5/1994 (*) Notice: Subject to any disclaimer, the term of this DE 9859.499 : 12/1998 patent is extended or adjusted under 35 E. O S. A1 3.10: U.S.C. 154(b) by 234 days. FR 2244469 8/1973 FR 4506 8/1993 (21) Appl. No.: 10/196,053 FR 277 1009 11/1997 JP 56128719 3/1980 (22) Filed: Jul. 15, 2002 JP 306.6627 8/1989 O O JP 9052829 6/1995 (65) Prior Publication Data WO WO 95.01803 A1 * 1/1995 US 2004/0013741 A1 Jan. 22, 2004 WO WO 9725,979 1/1996 WO WOOO765OO 12/2000 (51) Int. Cl. WO WOO121601 3/2001 A6IF I3/00 (2006.01) ZA 61O1840 8/1993 A6F 99.6A06 3032006.O1 OTHER PUBLICATIONS A6 IK 948 (2006.01) JW Read, JL Abitbol, KD Bardhan, PJ Whorwell, B Fraitag-"Efficacy and Safety of the peripheral kappa ago (52) U.S. Cl. ....................... 424/436; 424/422; 424/430; nist fedotoZine verSuS placebo in the treatment of functional 424/433; 424/451; 424/464; 424/489 dyspepsia see comments)." Gut Nov., 1997 41(5):664-8.
    [Show full text]
  • 16.2.5 Compliance And/Or Drug Concentration Data
    Clinical Study Report Covance CRU Study No. 7694-105 Sponsor Protocol No. SM 08-01 16.2.5 Compliance and/or Drug Concentration Data Clinical Study Report Confidential Covance CRU Study No. 7694-105 Sponsor Protocol No. SM 08-01 Listing 16.2.5-1 Product Dispensation by Subject (Page 1 of 86) Study Population: ITT Subject Amount Dispensed Number Timepoint Study product (logs) R1001 Week 0 0.5 g of snus or placebo logs dispensed 8 1.0 g of snus or placebo logs dispensed 4 Week 6 0.5 g of snus or placebo logs dispensed 4 1.0 g of snus or placebo logs dispensed 0 Week 10 0.5 g of snus or placebo logs dispensed 2 1.0 g of snus or placebo logs dispensed 4 R1002 Week 0 0.5 g of snus or placebo logs dispensed 8 1.0 g of snus or placebo logs dispensed 4 Week 6 0.5 g of snus or placebo logs dispensed 2 1.0 g of snus or placebo logs dispensed 0 Week 10 0.5 g of snus or placebo logs dispensed 2 1.0 g of snus or placebo logs dispensed 0 R1003 Week 0 0.5 g of snus or placebo logs dispensed 8 1.0 g of snus or placebo logs dispensed 4 Clinical Study Report Confidential Covance CRU Study No. 7694-105 Sponsor Protocol No. SM 08-01 Listing 16.2.5-1 Product Dispensation by Subject (Page 2 of 86) Study Population: ITT Subject Amount Dispensed Number Timepoint Study product (logs) R1004 Week 0 0.5 g of snus or placebo logs dispensed 8 1.0 g of snus or placebo logs dispensed 4 Week 6 0.5 g of snus or placebo logs dispensed 3 1.0 g of snus or placebo logs dispensed 3 Week 10 0.5 g of snus or placebo logs dispensed 6 1.0 g of snus or placebo logs dispensed 0 R1005 Week 0 0.5 g of snus or placebo logs dispensed 8 1.0 g of snus or placebo logs dispensed 4 Week 6 0.5 g of snus or placebo logs dispensed 4 1.0 g of snus or placebo logs dispensed 2 Week 10 0.5 g of snus or placebo logs dispensed 5 1.0 g of snus or placebo logs dispensed 2 R1006 Week 0 0.5 g of snus or placebo logs dispensed 8 1.0 g of snus or placebo logs dispensed 4 Clinical Study Report Confidential Covance CRU Study No.
    [Show full text]
  • WO 2016/015055 Al 28 January 2016 (28.01.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/015055 Al 28 January 2016 (28.01.2016) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 38/10 (2006.01) A61P 1/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61K 38/04 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US20 15/042298 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 27 July 2015 (27.07.2015) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/028,963 25 July 2014 (25.07.2014) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: IRONWOOD PHARMACEUTICALS, INC.
    [Show full text]
  • Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
    (19) TZZ ¥__T (11) EP 2 998 314 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 23.03.2016 Bulletin 2016/12 C07K 7/08 (2006.01) A61K 38/10 (2006.01) A61K 47/48 (2006.01) A61P 1/00 (2006.01) (21) Application number: 15190713.6 (22) Date of filing: 04.06.2008 (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • SHAILUBHAI, Kunwar HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT Audubon, PA 19402 (US) RO SE SI SK TR • JACOB, Gary S. New York, NY 10028 (US) (30) Priority: 04.06.2007 US 933194 P (74) Representative: Cooley (UK) LLP (62) Document number(s) of the earlier application(s) in Dashwood accordance with Art. 76 EPC: 69 Old Broad Street 12162903.4 / 2 527 360 London EC2M 1QS (GB) 08770135.5 / 2 170 930 Remarks: (71) Applicant: Synergy Pharmaceuticals Inc. This application was filed on 21-10-2015 as a New York, NY 10170 (US) divisional application to the application mentioned under INID code 62. (54) AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS (57) The invention provides novel guanylate cycla- esterase. The gastrointestinal disorder may be classified se-C agonist peptides and their use in the treatment of as either irritable bowel syndrome, constipation, or ex- human diseases including gastrointestinal disorders, in- cessive acidity etc. The gastrointestinal disease may be flammation or cancer (e.g., a gastrointestinal cancer).
    [Show full text]
  • Calcium Polycarbophil
    CALCIUM POLYCARBOPHIL- calcium polycarbophil tablet, film coated Cardinal Health Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies. ---------- 0339-Cardinal Drug Facts Active ingredient (in each caplet) Calcium polycarbophil 625 mg (equivalent to polycarbophil 500 mg) Purpose Bulk-forming laxative Uses relieves occasional constipation (irregularity) generally produces bowel movement in 12 to 72 hours Choking: Taking this product without adequate fluid may cause it to swell and block your throat or esophagus and may cause choking. Do not take this product if you have difficulty in swallowing. If you experience chest pain, vomiting, or difficulty in swallowing or breathing after taking this product, seek immediate medical attention. Ask a doctor before use if you have abdominal pain, nausea, or vomiting a sudden change in bowel habits that persists over a period of 2 weeks Ask a doctor or pharmacist before use if you are taking any other drug. Take this product two or more hours before or after other drugs. Laxatives may affect how other drugs work. When using this product do not use for more than 7 days unless directed by a doctor do not take more than 8 caplets in a 24-hour period unless directed by a doctor Stop use and ask a doctor if you fail to have a bowel movement after use or have rectal bleeding. These could be signs of a serious condition. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center (1-800-222- 1222) right away.
    [Show full text]
  • Price Master for OCHA File
    Price Master for OCHA File Item Code Item Description Item Price 1210000001 FS-SIXTH SEMI-PRIVATE 2365 1210000006 MED/SUR OVERFLOW SEMI-PVT 2365 1210000007 ED OVERFLOW SEMI-PRIV BED 2365 1210000008 SAME DAY ADMIT SEMI-PRIV BED 2365 1210000009 GS-SEVENTH SEMI-PRIV 1BED 2365 1210000010 ICU-MED/SUR SEMI-PRIV BED 2365 1220000001 OB SEMI-PRIVATE 2420 1230000001 G3 PEDIATRICS SEMI PRIVATE 2150 1240000001 PSYCHIATRIC SEMI PRIVATE 2090 1240000002 ED HOLD PSYCH SEMI PRIVATE 2090 1240000003 SBHU SEMI PRIVATE 2090 1260000001 PSYCH DETOX SEMI PRIVATE 2200 1260000002 ED HOLD PSYCH DETOX SEMI PRIV 2200 1700000002 NURSERY ROOM RATE 1650 2000000001 ICU OVERFLOW PACU 3630 2000000002 INTENSIVE CARE 3630 2060000001 FS ISOLATION 2365 2060000002 FS TELEMETRY BED 2365 2060000003 FS TELEMETRY/ISOLATION 2365 2060000005 GS ISOLATION 2365 2060000006 GS TELEMETRY 2365 2060000007 GS TELEMETRY/ISOLATION 2365 2060000008 ICU ISOLATION 2365 2060000009 ED ISOLATION 2365 2060000010 ED TELEMETRY BED 2365 2060000011 ED TELEMETRY/ISOLATION 2150 2500000001 SODIUM CHLORIDE 0.9% RESP 3 ML NEBULIZATION SOLUTION 1.285 2500000002 ALBUTEROL 1.25 MG/3 ML VIAL.NEB 12.336 2500000003 ALBUTEROL 0.63 MG/3 ML VIAL.NEB 8.523 2500000004 ALBUTEROL/IPRATROPIUM 3 ML INH SOL 2.197 2500000005 RACEPINEPHRINE 2.25% 0.5 ML NEB 14.103 2500000006 ALBUTEROL 5 MG/ML 20 ML NEB SOL 80.6415 2500000007 IPRATROPIUM BROMIDE 0.5 MG/2.5 ML NEB 1.517 2500000009 ALBUTEROL 2.5 MG/3 ML VIAL.NEB 1.533 2500000010 ACETYLCYSTEINE-NONFORMULARY 10% 4 ML VIAL 11.8916 2500000011 TIAGABINE HCL 4 MG TAB 31.496 2500000012
    [Show full text]
  • Bloating Y Distensión Abdominal:¿ Solamente Gas?: Una Mirada Hacia
    Clinical problem Bloating and abdominal distention: Just gas? A look in the direction of physiology David B. Páramo Hernández, MD.1 1 Professor of Clinical Gastroenterology at Santa Clara Abstract Hospital, Clínica Universitaria Universidad de La Sabana, Bogotá Colombia Many patients with functional digestive disorders such as irritable bowel syndrome (IBS) complain of bloating, abdominal distention and similar symptoms. Until recently these symptoms have been poorly understood, Translation from Spanish to English by T.A. Zuur and however new research allows us to clarify some aspects of their pathophysiology. This review discusses The Language Workshop some aspects of these symptoms which are related to intestinal gas and its transit, visceral hypersensitivity, ......................................... viscerosomatic response and to the intestinal microbiota. Received: 02-11-11 Accepted: 22-11-11 Key words Distention, bloating, irritable bowel syndrome (IBS), pathophysiology. INTRODUCTION criteria are based on symptoms. It goes on to say that it is a feeling of abdominal distention which may or may not be Bloating and abdominal distention associated with measurable distention. Th is allows us to infer that the symptom and the sign may be present under Among the various types of functional digestive disorders the same denomination. common discomforts such as bloating and abdominal dis- Now, to perform the offi cial Spanish translation supported tention which are apparently safe can produce signifi cant by the Translations Committ ee of the Rome Foundation, alterations to a patient’s quality of life especially when they the Mexican Gastroenterology magazine translates the are within the framework of conditions such as irritable term “C2: Functional Bloating” as “C2 Infl amación / bowel syndrome (1).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,569,445 B2 Manning Et Al
    USOO6569445B2 (12) United States Patent (10) Patent No.: US 6,569,445 B2 Manning et al. (45) Date of Patent: May 27, 2003 (54) FOOD BARS CONTAINING NUTRITIONAL OTHER PUBLICATIONS SUPPLEMENTS AND ANT-CONSTIPATION AND REGULARITY MANTAINING-AGENTS National Acedemy of Sciences, Subcommittee on Dietary Intake and Nutrient Supplements During Pregnancy, Nutri (75) Inventors: Paul B. Manning, Keswick, VA (US); tion During Pregnancy, p. 240, Washington, D.C. 1990.* Jack H. Schramm, Gordonsville, VA Physician's Desk Reference, 49' Edition, 1995, P 1264 (US); James W. McGrath, Jr., (Medical Economics Data Production Company, Montvale, Keswick, VA (US) New Jersey). (73) Assignee: PBM Pharmaceuticals, Inc., Gordonsville, VA (US) Primary Examiner Thurman K. Page ASSistant Examiner-Rachel M. Bennett (*) Notice: Subject to any disclaimer, the term of this (74) Attorney, Agent, or Firm-Roberta L. Hastreiter; Scott patent is extended or adjusted under 35 B. Feder; Lord, Bissell & Brook U.S.C. 154(b) by 21 days. (57) ABSTRACT (21) Appl. No.: 09/730,194 The present invention provides food bars for consumption (22) Filed: Dec. 5, 2000 by pregnant women, lactating women or women of child e as bearing potential that are attempting to become pregnant (65) Prior Publication Data containing one or more Vitamins and/or minerals, and one or more anti-constipation and regularity-maintaining agents, US 2002/0102330 A1 Aug. 1, 2002 methods for preparing these food bars, and methods for (51) Int. Cl." .......................... A61K 47/00; A23L 1/302 Supplementing the dietary requirements of pregnant Women, (52) U.S. Cl. ............................ 424/439: 426/72; 426/74 lactating Women or Women of childbearing potential that are (58) Field of Search ...........................
    [Show full text]